Objective Silvercatpharma project aims at developing C-C cross-coupling reactions catalysed by d11-blocks metals, particularly silver, for the synthesis of pharmaceuticals in Novartis. It strives to have an impact in terms of cost, environment and international visibility because of the use of silver as an alternative catalyst. The project offers me a great opportunity to obtain further training, such as clusters preparation, computational and flow chemistry, and to define my final career in academia or industry because of the possibility of working in these two different environments. Fields of science natural scienceschemical sciencesorganic chemistrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesbasic medicinemedicinal chemistrynatural scienceschemical sciencesinorganic chemistrytransition metalsnatural scienceschemical sciencescatalysis Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Call for proposal H2020-MSCA-IF-2014 See other projects for this call Funding Scheme MSCA-IF-EF-ST - Standard EF Coordinator FUNDACIO PRIVADA INSTITUT CATALA D'INVESTIGACIO QUIMICA Net EU contribution € 158 121,60 Address Avenida paissos catalans 16 43007 Tarragona Spain See on map Region Este Cataluña Tarragona Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
